These findings indicate that simultaneous inhibition of reprogramming-inducing factors (genes), such as OCT4, KLF4, SOX2, c-MYC, and NANOG, as well as genes such as JDP2, telomerase reverse transcriptase gene, and HIF1α, leading to decreased stemness of residual CSCs, might be a promising strategy for cancer therapeutics [123,124]. The gene discussed is MYC; the disease is cancer.